Screening for Prostate Cancer: Current Status and Future Prospects

American Journal of Medicine

Volumn 120, Issue 9, 2007, Pages 743-745

  Sharifi, Nima ^a   Kramer, Barnett S ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

CANCER MORTALITY; CANCER SCREENING; EDITORIAL; GLEASON SCORE; HEALTH CARE SYSTEM; HUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 34548161822     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2006.12.014     Document Type: Editorial

References (16)

1. American Cancer Society. Overview: prostate cancer. Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_2_1X_How_many_men_get_prostate_cancer_36.asp?sitearea=. Accessed June 7, 2007.
2. Cancer facts & figures, 2003. Atlanta: American Cancer Society; 2003.
3. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
4. Quek M.L., and Penson D.F. Quality of life in patients with localized prostate cancer. Urol Oncol 23 (2005) 208-215
5. Brawley O.W., and Kramer B.S. Cancer screening in theory and in practice. J Clin Oncol 23 (2005) 293-300
6. Thompson I.M., Ankerst D.P., Chi C., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294 (2005) 66-70
7. Albertsen P.C., Hanley J.A., and Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005) 2095-2101
8. Tannock I.F. Eradication of a disease: how we cured symptomless prostate cancer. Lancet 359 (2002) 1341-1342
9. Harris R.P., Helfand M., Woolf S.H., et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 20 3 Suppl (2001) 21-35
10. Welch H.G. Should I Be Tested for Cancer: Maybe Not and Here's Why (2004), University of California Press, Berkley, CA
11. Wang X., Yu J., Sreekumar A., et al. Autoantibody signatures in prostate cancer. N Engl J Med 353 (2005) 1224-1235
12. Dhanasekaran S.M., Barrette T.R., Ghosh D., et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412 (2001) 822-826
13. Donovan J., Mills N., Smith M., et al. Quality improvement report: improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult. BMJ 325 (2002) 766-770
14. Bill-Axelson A., Holmberg L., Ruutu M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 (2005) 1977-1984
15. Kramer B.S., Brown M.L., Prorok P.C., Potosky A.L., and Gohagan J.K. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 119 (1993) 914-923
16. Andriole G.L., Levin D.L., Crawford E.D., et al. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 97 (2005) 433-438